Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

Gene Therapy

Volumn 17, Issue 7, 2010, Pages 892-904

  Pesonen, S ^a,b   Nokisalmi, P ^a,b   Escutenaire, S ^a,b   Sarkioja M ^a,b   Raki, M ^a,b   Cerullo, V ^a,b   Kangasniemi, L ^a,b   Laasonen, L ^a   Ribacka, C ^a,b   Guse, K ^a,b   Haavisto, E ^a,b   Oksanen, M ^a,b   Rajecki, M ^a,b   Helminen, A ^a,c   Ristimaki A ^b,d,e   Karioja Kallio, A ^a,b   Karli, E ^a,b   Kantola, T ^b   Bauerschmitz, G ^a,b,f   Kanerva, A ^a,b   Joensuu, T ^c   Hemminki, A ^a,b   more..

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c International Comprehensive Cancer Center Docrates   (Finland)

^d Genome Scale Biology Program   (Finland)

^e UNIVERSITY OF OULU   (Finland)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

cancer; cyclooxygenase 2; oncolytic adenovirus

Indexed keywords

CYCLOOXYGENASE 2; E1A PROTEIN; ONCOLYTIC ADENOVIRUS; TUMOR MARKER; VIRUS ANTIBODY;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 5; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER PAIN; CHILL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; ILEUS; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE; LEUKOPENIA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NAUSEA; NEUROBLASTOMA; OVARY ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SIGMOID CARCINOMA; SOLID TUMOR; STOMACH CANCER; STOMACH PAIN; SYSTEMIC CIRCULATION; THROMBOCYTE; THROMBOCYTOPENIA; TUMOR VOLUME; URTICARIA; UTERINE TUBE CARCINOMA; VIRAL GENE THERAPY; VIRUS PARTICLE; VOMITING; ADENOVIRIDAE; BLOOD; ENZYMOLOGY; ISOLATION AND PURIFICATION; LIVER; METASTASIS; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; VIROLOGY;

ADENOVIRIDAE; ADULT; AGED; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; TREATMENT OUTCOME;

EID: 77954530690     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.17     Document Type: Article

References (56)

1. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42-58.
2. Stone D, Lieber A. New serotypes of adenoviral vectors. Curr Opin Mol Ther 2006; 8: 423-431.
3. Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Therapy 2004; 11: 643-664.
4. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
5. Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol 2009; 4: 527-536.
6. Di Paolo NC, Tuve S, Ni S, Hellström KE, Hellström I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006; 66: 960-969.
7. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009.
8. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006; 2: 137-143.
9. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
10. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107-117.
11. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148.
12. Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006; 14: 164-174.
13. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
14. Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 2008; 68: 5533-5539.
15. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
16. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
17. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
18. Rousseau P. Management of malignant bowel obstruction in advanced cancer: a brief review. J Palliat Med 1998; 1: 65-72.
19. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
20. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
21. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 115-122.
22. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003; 13: 155-171.
23. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
24. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
25. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009; 18: 215-222.
26. Kotowicz B, Fuksiewicz M, Kowalska M, Jonska-Gmyrek J, Bidzinski M, Kaminska J. The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients. Int J Gynecol Cancer 2008; 18: 1279-1284.
27. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15: 378-385.
28. Brunetti-Pierri N, Stapleton GE, Law M, Breinholt J, Palmer DJ, Zuo Y et al. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 2009; 17: 327-333.
29. Brunetti-Pierri N, Palmer DJ, Mane V, Finegold M, Beaudet AL, Ng P. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydro-dynamic injection of helper-dependent adenoviral vectors. Mol Ther 2005; 12: 99-106.
30. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Therapy 2004; 15: 35-46.
31. Nemunaitis J, Senzer N, Sarmiento S, Zhang Y, Arzaga R, Sands B et al. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Therapy 2007; 14: 885-893.
32. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006; 13: 1185-1191.
33. Galanis E, Okuno S, Nascimento A, Lewis B, Lee R, Oliveira A et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy 2005; 12: 437-445.
34. Dhar D, Spencer JF, Toth K, Wold WS. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130-2139.
35. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007; 12: 1084-1095.
36. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
37. Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A et al. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 2008; 108: 166-172.
38. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
39. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy 2001; 8: 89-98.
40. Turunen T NP, Cerullo V, Pesonen S, Oksanen M, Escutenaire S, Hemminki A. Effect of oncolytic adenovirus on tumor marker levels in cancer patients and in preclinical test systems. Mol Ther 2009; 17(Suppl 1): S110.
41. Alemany R. A smart move against cancer for vaccinia virus. Lancet Oncol 2008; 9: 507-508.
42. Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009; 27: 4225-4239.
43. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453-5460.
44. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Therapy 2005; 12: 715-722.
45. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther 2009; 8: 980-987.
46. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
47. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008; 13: 2060-2064.
48. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Therapy 2002; 9: 1022-1035.
49. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
50. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adeno-virus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008; 105: 7293-7297.
51. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006; 59: 382-386.
52. D'Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004; 10: 8132-8141.
53. Warren KE, Patronas N, Aikin AA, Albert PS, Balis FM. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001; 93: 1401-1405.
54. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
55. Sarkioja M, Pesonen S, Raki M, Hakkarainen T, Salo J, Ahonen MT et al. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Therapy 2008; 15: 921-929.
56. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.